At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Hydrocodonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Pharmacokinetic Profile of Hydromorphone in Chronic Pain Patients Taking Hydrocodone/APAP
In Brief
A Phase 4 clinical trial evaluating Hydrocodone for Chronic Pain. Completed, enrolled 30 participants across 2 sites.
Detailed Summary
Objective is to evaluate the pharmacokinetics profile of hydrocodone's metabolite hydromorphone in patients who are taking hydrocodone on a routine basis for more than 3 months for chronic pain and correlate hydromorphone levels to their hydrocodone usage.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain
CountriesUnited States
CollaboratorsMedtronic - MITG, International Clinical Research Institute
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartFeb 2012
Primary CompletionMay 2012
Study CompletionSep 2012
TodayJul 2026
First PostedJan 25, 2012
Enrollment StartFeb 1, 2012
Primary CompletionMay 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.4 years ago
Interventions
Hydrocodonedrug
Dose: Standard prescribed dose Frequency: Once Duration: Once